JP2020531486A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531486A5 JP2020531486A5 JP2020510096A JP2020510096A JP2020531486A5 JP 2020531486 A5 JP2020531486 A5 JP 2020531486A5 JP 2020510096 A JP2020510096 A JP 2020510096A JP 2020510096 A JP2020510096 A JP 2020510096A JP 2020531486 A5 JP2020531486 A5 JP 2020531486A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridyl
- pyridin
- oxo
- trifluoromethyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 42
- 150000003839 salts Chemical class 0.000 claims 38
- GTCAXTIRRLKXRU-UHFFFAOYSA-N carbamic acid methyl ester Natural products COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 claims 20
- -1 1-azetidinyl Chemical group 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 11
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 230000002950 deficient Effects 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- WEUPTDZSLQUHHB-UHFFFAOYSA-N 4-(2-aminopyridin-4-yl)-6-(2-chlorophenyl)-1H-pyridin-2-one Chemical compound NC1=NC=CC(=C1)C1=CC(NC(=C1)C1=C(C=CC=C1)Cl)=O WEUPTDZSLQUHHB-UHFFFAOYSA-N 0.000 claims 3
- LRUDZBBEMDATJL-UHFFFAOYSA-N 4-(2-aminopyridin-4-yl)-6-pyridin-3-yl-1H-pyridin-2-one Chemical compound NC1=NC=CC(=C1)C1=CC(NC(=C1)C=1C=NC=CC=1)=O LRUDZBBEMDATJL-UHFFFAOYSA-N 0.000 claims 3
- ULRZATBBRNFUII-UHFFFAOYSA-N N-[4-[2-(2-chlorophenyl)-6-oxo-1H-pyridin-4-yl]pyridin-2-yl]-2-methoxyacetamide Chemical compound ClC1=C(C=CC=C1)C=1NC(C=C(C=1)C1=CC(=NC=C1)NC(COC)=O)=O ULRZATBBRNFUII-UHFFFAOYSA-N 0.000 claims 3
- KYABMOVZHRXKDQ-UHFFFAOYSA-N N-[4-[2-(3-cyclopropylmorpholin-4-yl)-6-oxo-1H-pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound C1(CC1)C1N(CCOC1)C=1NC(C=C(C=1)C1=CC(=NC=C1)NC(C)=O)=O KYABMOVZHRXKDQ-UHFFFAOYSA-N 0.000 claims 3
- JTUBLRKWQWLDGI-UHFFFAOYSA-N N-[4-[2-(4-methylpyridin-3-yl)-6-oxo-1H-pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound CC1=C(C=NC=C1)C=1NC(C=C(C=1)C1=CC(=NC=C1)NC(C)=O)=O JTUBLRKWQWLDGI-UHFFFAOYSA-N 0.000 claims 3
- WHWGYPKJDYJZPK-UHFFFAOYSA-N N-[4-[2-[1-ethyl-3-(trifluoromethyl)pyrazol-4-yl]-6-oxo-1H-pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound C(C)N1N=C(C(=C1)C=1NC(C=C(C=1)C1=CC(=NC=C1)NC(C)=O)=O)C(F)(F)F WHWGYPKJDYJZPK-UHFFFAOYSA-N 0.000 claims 3
- ZKBIQNBVDMYXCG-UHFFFAOYSA-N N-[4-[2-[4-ethylsulfonyl-2-(trifluoromethyl)piperazin-1-yl]-6-oxo-1H-pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound C(C)S(=O)(=O)N1CC(N(CC1)C=1NC(C=C(C=1)C1=CC(=NC=C1)NC(C)=O)=O)C(F)(F)F ZKBIQNBVDMYXCG-UHFFFAOYSA-N 0.000 claims 3
- WYKJXFMXVUDREO-UHFFFAOYSA-N N-[4-[2-oxo-6-[2-(trifluoromethyl)phenyl]-1H-pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound O=C1NC(=CC(=C1)C1=CC(=NC=C1)NC(C)=O)C1=C(C=CC=C1)C(F)(F)F WYKJXFMXVUDREO-UHFFFAOYSA-N 0.000 claims 3
- WSZRNKMWOZHSEK-UHFFFAOYSA-N N-[4-[2-oxo-6-[2-(trifluoromethyl)piperidin-1-yl]-1H-pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound O=C1NC(=CC(=C1)C1=CC(=NC=C1)NC(C)=O)N1C(CCCC1)C(F)(F)F WSZRNKMWOZHSEK-UHFFFAOYSA-N 0.000 claims 3
- SXTBJUQDFNIUBC-UHFFFAOYSA-N N-[4-[2-oxo-6-[2-(trifluoromethyl)piperidin-1-yl]-1H-pyridin-4-yl]pyridin-2-yl]cyclopropanecarboxamide Chemical compound O=C1NC(=CC(=C1)C1=CC(=NC=C1)NC(=O)C1CC1)N1C(CCCC1)C(F)(F)F SXTBJUQDFNIUBC-UHFFFAOYSA-N 0.000 claims 3
- FMUDKKVYHUYDHN-UHFFFAOYSA-N N-[4-[2-oxo-6-[2-(trifluoromethyl)pyridin-3-yl]-1H-pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound O=C1NC(=CC(=C1)C1=CC(=NC=C1)NC(C)=O)C=1C(=NC=CC=1)C(F)(F)F FMUDKKVYHUYDHN-UHFFFAOYSA-N 0.000 claims 3
- MVNXIWSZHATYNO-UHFFFAOYSA-N N-[4-[2-oxo-6-[3-(trifluoromethyl)morpholin-4-yl]-1H-pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound O=C1NC(=CC(=C1)C1=CC(=NC=C1)NC(C)=O)N1C(COCC1)C(F)(F)F MVNXIWSZHATYNO-UHFFFAOYSA-N 0.000 claims 3
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- GRXPRRPKOQULJV-UHFFFAOYSA-N N-[4-[2-(2-chlorophenyl)-6-oxo-1H-pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound ClC1=C(C=CC=C1)C=1NC(C=C(C=1)C1=CC(=NC=C1)NC(C)=O)=O GRXPRRPKOQULJV-UHFFFAOYSA-N 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- ONHSGOPTCOTAQD-UHFFFAOYSA-N 1,1-dimethyl-3-[4-[2-oxo-6-[2-(trifluoromethyl)phenyl]-1H-pyridin-4-yl]pyridin-2-yl]urea Chemical compound CN(C(=O)NC1=NC=CC(=C1)C1=CC(NC(=C1)C1=C(C=CC=C1)C(F)(F)F)=O)C ONHSGOPTCOTAQD-UHFFFAOYSA-N 0.000 claims 1
- ULUDICOQHXTMDW-UHFFFAOYSA-N 3-[4-[2-(2-chlorophenyl)-6-oxo-1H-pyridin-4-yl]pyridin-2-yl]-1,1-dimethylurea Chemical compound ClC1=C(C=CC=C1)C=1NC(C=C(C=1)C1=CC(=NC=C1)NC(N(C)C)=O)=O ULUDICOQHXTMDW-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- WGFAFMAQISHQSM-UHFFFAOYSA-N N-[4-[2-(2-chlorophenyl)-6-oxo-1H-pyridin-4-yl]pyridin-2-yl]pyrrolidine-1-carboxamide Chemical compound ClC1=C(C=CC=C1)C=1NC(C=C(C=1)C1=CC(=NC=C1)NC(=O)N1CCCC1)=O WGFAFMAQISHQSM-UHFFFAOYSA-N 0.000 claims 1
- GWHGMPUKIGJYGA-UHFFFAOYSA-N N-[4-[2-(2-methylpyridin-3-yl)-6-oxo-1H-pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound CC1=NC=CC=C1C=1NC(C=C(C=1)C1=CC(=NC=C1)NC(C)=O)=O GWHGMPUKIGJYGA-UHFFFAOYSA-N 0.000 claims 1
- DEGTWMWMGZJAKR-UHFFFAOYSA-N N-[4-[2-oxo-6-[2-(trifluoromethyl)phenyl]-1H-pyridin-4-yl]pyridin-2-yl]pyrrolidine-1-carboxamide Chemical compound O=C1NC(=CC(=C1)C1=CC(=NC=C1)NC(=O)N1CCCC1)C1=C(C=CC=C1)C(F)(F)F DEGTWMWMGZJAKR-UHFFFAOYSA-N 0.000 claims 1
- YHZOOIVUJYXALU-UHFFFAOYSA-N N-[4-[2-oxo-6-[4-(trifluoromethyl)thiophen-3-yl]-1H-pyridin-4-yl]pyridin-2-yl]acetamide Chemical compound O=C1NC(=CC(=C1)C1=CC(=NC=C1)NC(C)=O)C1=CSC=C1C(F)(F)F YHZOOIVUJYXALU-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 230000008512 biological response Effects 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- 150000004696 coordination complex Chemical class 0.000 claims 1
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000003667 hormone antagonist Substances 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 201000003733 ovarian melanoma Diseases 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- 0 Cc1ccc(**)cc1C Chemical compound Cc1ccc(**)cc1C 0.000 description 5
- VQTVFIMEENGCJA-UHFFFAOYSA-N Cc1c[nH]nc1C Chemical compound Cc1c[nH]nc1C VQTVFIMEENGCJA-UHFFFAOYSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022198540A JP2023021276A (ja) | 2017-08-23 | 2022-12-13 | ピリジルピリドン化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17187544 | 2017-08-23 | ||
| EP17187544.6 | 2017-08-23 | ||
| PCT/EP2018/072788 WO2019038387A1 (en) | 2017-08-23 | 2018-08-23 | PYRIDYLPYRIDONE COMPOUNDS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022198540A Division JP2023021276A (ja) | 2017-08-23 | 2022-12-13 | ピリジルピリドン化合物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020531486A JP2020531486A (ja) | 2020-11-05 |
| JP2020531486A5 true JP2020531486A5 (enExample) | 2021-09-30 |
| JPWO2019038387A5 JPWO2019038387A5 (enExample) | 2022-10-20 |
| JP7199737B2 JP7199737B2 (ja) | 2023-01-06 |
Family
ID=59686881
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020510096A Active JP7199737B2 (ja) | 2017-08-23 | 2018-08-23 | ピリジルピリドン化合物 |
| JP2022198540A Pending JP2023021276A (ja) | 2017-08-23 | 2022-12-13 | ピリジルピリドン化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022198540A Pending JP2023021276A (ja) | 2017-08-23 | 2022-12-13 | ピリジルピリドン化合物 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11219618B2 (enExample) |
| EP (2) | EP3672941B1 (enExample) |
| JP (2) | JP7199737B2 (enExample) |
| KR (1) | KR102730718B1 (enExample) |
| CN (3) | CN116891431A (enExample) |
| AU (2) | AU2018320416B2 (enExample) |
| CA (1) | CA3072974A1 (enExample) |
| CY (1) | CY1125138T1 (enExample) |
| DK (1) | DK3672941T3 (enExample) |
| ES (1) | ES2910839T3 (enExample) |
| HR (1) | HRP20220571T1 (enExample) |
| HU (1) | HUE058977T2 (enExample) |
| IL (3) | IL302356A (enExample) |
| LT (1) | LT3672941T (enExample) |
| PL (1) | PL3672941T3 (enExample) |
| PT (1) | PT3672941T (enExample) |
| RS (1) | RS63161B1 (enExample) |
| SI (1) | SI3672941T1 (enExample) |
| SM (1) | SMT202200183T1 (enExample) |
| TW (2) | TWI787335B (enExample) |
| WO (1) | WO2019038387A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3728230A1 (en) | 2017-12-22 | 2020-10-28 | Ravenna Pharmaceuticals, Inc. | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| WO2022115562A1 (en) | 2020-11-25 | 2022-06-02 | Deciphera Pharmaceuticals, Llc | Morpholino derivatives as vsp34 inhibitors for use in the treatment of a viral infection |
| JP2023553809A (ja) | 2020-11-25 | 2023-12-26 | デシフェラ・ファーマシューティカルズ，エルエルシー | ウイルス感染の治療に使用するためのｖｓｐ３４阻害剤としてのピリジルピリドン誘導体 |
| US20250127790A1 (en) * | 2021-08-13 | 2025-04-24 | Deciphera Pharmaceuticals, Llc | Combination therapy using vps34 inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4606161B2 (ja) * | 2002-05-21 | 2011-01-05 | アムジエン・インコーポレーテツド | 置換複素環式化合物および使用方法 |
| TW200908984A (en) * | 2007-08-07 | 2009-03-01 | Piramal Life Sciences Ltd | Pyridyl derivatives, their preparation and use |
| EA201390917A1 (ru) * | 2010-12-21 | 2013-12-30 | Новартис Аг | Дигетероарильные соединения в качестве ингибиторов vps34 |
| HUE024504T2 (en) | 2010-12-23 | 2016-01-28 | Sanofi Sa | Pyrimidine derivatives, a process for their preparation and their use in medicine |
| GB201120317D0 (en) | 2011-11-24 | 2012-01-04 | Queen Mary & Westfield College | Screening method |
| PL2820009T3 (pl) * | 2012-03-01 | 2018-09-28 | Array Biopharma, Inc. | Inhibitory kinaz serynowo/treoninowych |
| MX2014015156A (es) * | 2012-06-12 | 2015-08-06 | Abbvie Inc | Derivados de piridinona y piridazinona. |
| FR2992314B1 (fr) | 2012-06-22 | 2015-10-16 | Sanofi Sa | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
| TN2016000270A1 (en) | 2014-01-14 | 2017-10-06 | Millennium Pharm Inc | Heteroaryls and uses thereof. |
| JP2017502092A (ja) | 2014-01-14 | 2017-01-19 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ヘテロアリール及びその使用 |
| MA39822A (fr) | 2014-04-03 | 2018-02-06 | Janssen Pharmaceutica Nv | Dérivés de pyrimidine bicycle |
| MA39823A (fr) | 2014-04-03 | 2018-01-09 | Janssen Pharmaceutica Nv | Dérivés de pyridine macrocyclique |
| WO2016001789A1 (en) | 2014-06-30 | 2016-01-07 | Pfizer Inc. | Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer |
| CA3015045A1 (en) | 2016-02-19 | 2017-08-24 | Sprint Bioscience Ab | 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes |
| US11179399B2 (en) | 2016-02-19 | 2021-11-23 | Sprint Bioscience Ab | 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes |
-
2018
- 2018-08-23 KR KR1020207006936A patent/KR102730718B1/ko active Active
- 2018-08-23 PT PT187593082T patent/PT3672941T/pt unknown
- 2018-08-23 IL IL302356A patent/IL302356A/en unknown
- 2018-08-23 CN CN202310818638.5A patent/CN116891431A/zh active Pending
- 2018-08-23 EP EP18759308.2A patent/EP3672941B1/en active Active
- 2018-08-23 CN CN202310818724.6A patent/CN116903526A/zh active Pending
- 2018-08-23 LT LTEPPCT/EP2018/072788T patent/LT3672941T/lt unknown
- 2018-08-23 CA CA3072974A patent/CA3072974A1/en active Pending
- 2018-08-23 HU HUE18759308A patent/HUE058977T2/hu unknown
- 2018-08-23 DK DK18759308.2T patent/DK3672941T3/da active
- 2018-08-23 WO PCT/EP2018/072788 patent/WO2019038387A1/en not_active Ceased
- 2018-08-23 JP JP2020510096A patent/JP7199737B2/ja active Active
- 2018-08-23 AU AU2018320416A patent/AU2018320416B2/en active Active
- 2018-08-23 HR HRP20220571TT patent/HRP20220571T1/hr unknown
- 2018-08-23 CN CN201880059987.0A patent/CN111094244B/zh active Active
- 2018-08-23 TW TW107129492A patent/TWI787335B/zh not_active IP Right Cessation
- 2018-08-23 SI SI201830631T patent/SI3672941T1/sl unknown
- 2018-08-23 EP EP22155562.6A patent/EP4056556A1/en not_active Withdrawn
- 2018-08-23 RS RS20220398A patent/RS63161B1/sr unknown
- 2018-08-23 SM SM20220183T patent/SMT202200183T1/it unknown
- 2018-08-23 TW TW111144233A patent/TW202308996A/zh unknown
- 2018-08-23 ES ES18759308T patent/ES2910839T3/es active Active
- 2018-08-23 PL PL18759308T patent/PL3672941T3/pl unknown
- 2018-08-23 US US16/639,895 patent/US11219618B2/en active Active
-
2020
- 2020-02-20 IL IL272805A patent/IL272805B/en unknown
-
2021
- 2021-12-15 US US17/644,486 patent/US20220218688A1/en not_active Abandoned
-
2022
- 2022-04-25 IL IL292485A patent/IL292485B2/en unknown
- 2022-04-27 CY CY20221100305T patent/CY1125138T1/el unknown
- 2022-12-13 JP JP2022198540A patent/JP2023021276A/ja active Pending
-
2023
- 2023-10-31 AU AU2023258375A patent/AU2023258375A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11931363B2 (en) | Triazolopyrimidine compounds and uses thereof | |
| US10676479B2 (en) | Imidazolepyridine compounds and uses thereof | |
| AU2011217489B2 (en) | Pyrazole derivatives as JAK inhibitors | |
| JP2020531488A5 (enExample) | ||
| JP2020531486A5 (enExample) | ||
| JP2010513444A5 (enExample) | ||
| RU2018131766A (ru) | 6-гетероциклил-4-морфолин-4-илпиридин-2-оны, пригодные для лечения рака и диабета | |
| JP2019505595A5 (enExample) | ||
| RU2014131378A (ru) | Ингибиторы бромдомена | |
| RU2018131775A (ru) | 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета | |
| MX2014012097A (es) | Compuesto heterociclico que contiene nitrogeno o sal del mismo. | |
| JP2017512794A5 (enExample) | ||
| JP2017530999A5 (enExample) | ||
| CA2631746A1 (en) | Urea compounds useful in the treatment of cancer | |
| JP2016522246A5 (enExample) | ||
| JP2011520941A5 (enExample) | ||
| JP2019505594A5 (enExample) | ||
| HRP20221454T1 (hr) | Piridinamin-piridonski i pirimidinamin-piridonski spojevi | |
| JP2009544626A (ja) | Ｉｔｐｋｂ阻害剤としての化合物および組成物 | |
| JP2019530708A5 (enExample) | ||
| JPWO2021170109A5 (enExample) | ||
| TW200526641A (en) | Amidopyrazole derivatives | |
| RU2019113764A (ru) | Соединения хиноксалина в качестве ингибиторов рецепторной тирозинкиназы iii типа | |
| HRP20220571T1 (hr) | Spoj piridilpiridona | |
| HRP20161286T1 (hr) | Novi anti-invazivni spojevi |